IMPRiND Project

Springer Nature 2019 recognition

Congratulation to the UMG-GOE team who had a publication recognised in the Springer Nature 2019 highlights!

Publication on Targeting α-synuclein for PD Therapeutics

Challenges and Open questions: A Pursuit on All Fronts has been published in the journal Biomolecules by partners B. Dehay Read the publication.

Nature publication by partner M. Goedert

Novel tau filament fold in Corticobasal degeneration published in Nature by partner M. Goedert. Read the publication.

Interview on challenges in neurodegeneration research on the Neuronet blog

What are the most prominent challenges in neurodegeneration research from a pharma perspective? What can public-private collaboration bring to the table? Laurent Pradier from Sanofi answered on the @IMI2_NEURONET Leadership Blog. Read the interview.

State of play on Synucleinopathies: Where we are and where we need to go.

A review of the topics discussed at the Synuclein Meeting has been published in the Journal of Neurochemistry. The IMPRiND consortium had organised an internal satellite meeting at this conference that place in Ofir, Portugal in September 2019. This systematic assessment of where we stand will be useful to steer the field and contribute to filling knowledge gaps that may form the foundations for future therapeutic strategies. Read the publication.

Show more posts

This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu) under grant agreement No 116060. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 17.00038.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.

© 2019 IMPRiND Project – created by SCIPROMPrivacy policy